Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT)

• Status: Not yet recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: All

Summary

Hepatic artery thrombosis (HAT) represents a major cause of graft loss and mortality after Pediatric liver transplantation. Ticagrelor (a new reversible inhibitor of P2Y12 receptor with faster onset of action and greater platelet inhibition) was used to treat patients with pediatric post-transplant hepatic artery thrombosis (HAT) compared to low molecular weight heparin.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RenJi Hospital
• Treatments: Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Ticagrelor; Tinzaparin

Criteria

Inclusion Criteria:

• age from 2 months to 5 years old.

• voluntary participation in clinical trials, and informed consent;

• Contrast- Enhanced Ultrasonography proved HAT

Exclusion Criteria:

• History of sensitivity to study medications or any of their excipients

• Renal failure (eGFR <30 or requiring dialysis)

• A known bleeding diathesis, hemostatic or coagulation disorder, or prior major bleeding

• Prior stroke

• Active pathological bleeding

• History of intracranial haemorrhage

• Life expectancy <12 months based on investigator's judgement

• Patients considered to be at risk of bradycardic events (e.g., known sick sinus syndrome or second or third degree atrioventricular [AV)] block) unless already treated with a permanent pacemaker

• Anemia (hematocrit < 27%)

• Platelet count < 100,000/ml

• Concomitant use of strong CYP 3A inhibitors or inducers